Yahoo Web Search

Search results

    • Small Business - Shelby County Reporter | Shelby County Reporter

      The Shelby County Reporter· 19 minutes ago

      An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses

    • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 19 minutes ago

      Genmab A/S (Nasdaq: GMAB, “Genmab”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced initial data from the ongoing Phase 2 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4 ...